| Document |
Document Title |
|
WO/2019/212238A1 |
The present invention provides a method for providing a target nucleic acid sequence data set of a target nucleic acid molecule. The larger number of synonyms are retrieved from reliable sources than that of synonyms extracted by user ex...
|
|
WO/2019/191429A3 |
The present invention provides methods of diagnosing and prognosing disease by analyzing the methylation status of exosomal DNA. In particular, exosomal DNA, in particular exosomal DNA isolated from exosomes that originated from a diseas...
|
|
WO/2019/178288A9 |
Hepatitis E virus (HEV)-based virus like particles (VLP) made with a modified capsid protein containing at least a portion of open reading frame 2 (ORF2) protein and encapsulated insulin protein or insulin encoding nucleic acid are provi...
|
|
WO/2019/213374A1 |
Provided herein are compositions and methods for production of proteins in microbial systems. In particular, provided herein are compositions and methods for expressing exogenous genes from specific chromosomal locations of E. coli. Spec...
|
|
WO/2019/213348A1 |
Disclosed are compositions and methods for single-step PCR of a sample containing a complex target gene pool that can simultaneously amplify a wide variety of variant target gene sequences common to the sample while maintaining the origi...
|
|
WO/2019/213321A1 |
The present disclosure relates to methods for predicting the risk of recurrence and/or metastasis in primary cutaneous squamous cell carcinoma (cSCC).
|
|
WO/2019/213237A1 |
Disclosed herein include systems, methods, compositions, and kits for molecular barcoding on the 5'-end of a nucleic acid target. After barcoding a nucleic acid target using an oligonucleotide barcode comprising a target binding region a...
|
|
WO/2019/213119A1 |
Compounds that may inhibit Oplophorus-derived luciferases are disclosed as well as compositions and kits comprising the compounds and methods of using the compounds.
|
|
WO/2019/213504A1 |
The present invention is directed to the filed of gene therapy. In particular, compositions and methods are disclosed that repair gene microduplication mutations by reversion to a wild type sequence. For example, the creation of a double...
|
|
WO/2019/212899A1 |
Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable f...
|
|
WO/2019/210873A1 |
Various applications can use fragmentation patterns related of cell-free DNA, e.g., plasma DNA and serum DNA. For example, the end positions of DNA fragments can be used for various applications. The fragmentation patterns of short and l...
|
|
WO/2019/213619A1 |
Provided herein are compositions, systems, and methods for assessing and monitory disease stage and phases, predicting likelihood of disease progression, and predicting and monitoring responses to disease therapies (e.g., in HBV infection).
|
|
WO/2019/213096A1 |
Devices for assaying a biomolecule from a sample, including: a cartridge assembly structured to accept and secure a magnetofluidic cartridge to be used for the assaying, and a magnetic particle manipulation assembly arranged proximate th...
|
|
WO/2019/213478A1 |
The present disclosure relates to methods using gene expression measurements to identify mismatch repair deficiency, microsatellite instability and hypermutation in a subject.
|
|
WO/2019/211469A1 |
The invention provides compositions, processes and kits for determining the metabolic properties of cells of interest in vitro.
|
|
WO/2019/212922A1 |
The present disclosure relates to using spectrophotometry to estimate genome copies and full/empty ratios adeno-associated virus particles.
|
|
WO/2019/190930A3 |
RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-1313 and compositions, methods, and uses thereof.
|
|
WO/2019/210405A1 |
In an aspect, there is provided a computer-implemented method for approximating product production in a bioreactor. The method comprises: providing a bioreactor containing live cells in a substrate, the bioreactor for cultivating, over a...
|
|
WO/2019/190927A3 |
The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-sw...
|
|
WO/2019/161139A3 |
Disclosed are probes based on papilloma virus and modified SV40 that can be used for detecting circulating tumor cells (CTCs) in the blood stream, methods for manufacturing such probes, and methods for using such probes.
|
|
WO/2019/213489A1 |
Disclosed herein is an assay for determining the concentration of p-aminophenol present in a sample. More particularly, the present invention relates to an improvement of an enzyme-based assay for determining the concentration of acetami...
|
|
WO/2019/211348A1 |
The present invention relates to an electrode system for measuring the concentration of an analyte under in-vivo conditions, comprising an electrode 5 with immobilized enzyme molecules and a diffusion barrier that controls diffusion of t...
|
|
WO/2019/211418A1 |
The invention is a method of predicting recurrence of lung cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.
|
|
WO/2019/210764A1 |
Provided is an application of ATPase ATP13A2 in the preparation of biological markers for behavioural and motor abnormalities, the behavioural and motor abnormalities being caused by neural impulse control disorder and dyskinesia, and th...
|
|
WO/2019/213437A1 |
The disclosure provides a novel system of storing information using a charged polymer, e.g., DNA, the monomers of which correspond to a machine-readable code, e.g., a binary code, and which can be synthesized and/or read using a novel na...
|
|
WO/2019/212158A1 |
The present invention provides a method for detecting multiple nucleic acids by using a single fluorescence channel gene amplification apparatus (PCR machine) using a TaqMan probe and a PNA probe. A PNA probe designed to have low melting...
|
|
WO/2019/213624A1 |
Methods, compositions and kits for detection of a taxon of pathogenic microorganisms in a sample are provided. Also provided are methods, compositions and kits for detecting taxons of pathogenic microorganisms present in low titers in a ...
|
|
WO/2019/213525A1 |
Provided herein are methods and compositions for treating a subject in need thereof, such as a subject with deficient LAL protein expression or a subject having Cholesteryl Ester Storage Disease.
|
|
WO/2018/200505A9 |
The present disclosure relates to somatic ErbB2 mutations in cancer and provides methods of identifying, diagnosing, and prognosing ErbB2-positive cancers. The present disclosure further provides methods of treating cancer, including cer...
|
|
WO/2019/212615A1 |
Methods of amplifying nucleic acids in a sample are provided. Aspects of the methods include: a) fragmenting nucleic acids in the sample to produce a fragmented nucleic acid sample; b) contacting the fragmented nucleic acid sample with a...
|
|
WO/2019/210696A1 |
A prunus mume pendulous trait SNP molecular marker and the use thereof, including molecular markers Marker 301243 and/or Marker 311414, the nucleotide sequences thereof being respectively as shown in SEQ ID NO. 1 and SEQ ID NO. 2. Two pr...
|
|
WO/2019/212023A1 |
The present invention provides an RNA virus processing method that includes: (a) a step in which a sample possibly including an RNA virus is prepared; (b) a step in which a reverse transcription reaction liquid including the sample from ...
|
|
WO/2019/213005A1 |
The present invention relates to compounds, compositions and methods for treating diseases or conditions mediated by proteins of the SWI/SNF chromatin-remodeling complex, including PB1.
|
|
WO/2019/213254A1 |
The present disclosure relates to compositions and methods for assessing relative macromolecule abundance (e.g., RNA expression levels) in a spatially-defined manner across a tissue sample, specifically providing deep transcriptomic cove...
|
|
WO/2019/213294A1 |
Disclosed herein include systems, methods, compositions, and kits for sample analysis, in particular single cell analysis. Nucleic acid fragments comprising a capture sequence (or a complement thereof) can be generated from double-strand...
|
|
WO/2019/212138A1 |
The present invention relates to a recombinant vector comprising an oligonucleotide for discovering cross-contamination between next generation sequencing samples, and a next generation sequencing method capable of discovering cross-cont...
|
|
WO/2019/207439A1 |
A method for analyzing cell free DNA (cfDNA) from the bloodstream of a cancer patient is provided. In some embodiments, the method may comprise sequencing at least part of the coding sequences of TP53 and KRAS in a sample of the cfDNA, a...
|
|
WO/2019/210048A1 |
A vessel includes a memory and a processor operatively coupled to the memory. The memory is configured to store a vessel identifier. The processor is configured to initiate a timer for a shelf life of a solution placed into the vessel. T...
|
|
WO/2019/208696A1 |
[Problem] To provide a method for separating long-term and short-term hematopoietic stem cells, a method for identifying genes specifically expressed in long-term hematopoietic stem cells, a method for identifying genes involved in long-...
|
|
WO/2019/210203A1 |
Disclosed herein are methods, kits and compositions for treating a subject for an inflammatory bowel disease. These methods, kits and compositions may be particularly useful for subjects with single nucleotide polymorphisms in a G Protei...
|
|
WO/2019/208671A1 |
This invention according to one embodiment provides a kit, a device, and a method for detecting bladder cancer. This invention according to one embodiment relates to: a kit or a device that is for detecting bladder cancer and that contai...
|
|
WO/2019/207030A1 |
The invention relates to the prediction of responder or non-responder to immune checkpoint inhibitor in patient suffering from lung cancer. To study the interplay between malignant cells and their immune microenvironment, the inventors p...
|
|
WO/2019/209942A1 |
The present disclosure describes methods, devices and systems of diagnosing, prognosing, and treating subjects with moderate to severe forms of Crohn's disease (CD) that is characterized by stricturing and internal penetrating disease ph...
|
|
WO/2019/205132A1 |
A method for enriching fetal free nucleic acids, comprising performing PCR amplification on a sample containing fetal free nucleic acids to obtain a fetal free nucleic acid-enriched product; PCR amplification comprises first performing f...
|
|
WO/2019/206122A1 |
Application of CD93 in preparing a cord blood test kit for early warning infantile hemangioma (IH), in preparing a drug for treating or preventing IH, and in preparing a serum marker for preventing hemangioma. The cord blood test kit wit...
|
|
WO/2019/204985A1 |
The present invention relates to an osteoporosis biomarker and use thereof. The biomarker comprises Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides intestinalis, Bacteroides dorei, Ruminococcus sp., Akkermansia muciniphi...
|
|
WO/2019/208308A1 |
The present invention addresses the problem of providing: a glucose dehydrogenase; a polynucleotide encoding the enzyme; a method for producing the enzyme; a method for measuring glucose using the enzyme; a measurement reagent compositio...
|
|
WO/2019/208691A1 |
A method for detecting Candida auris in which nucleic acid amplification is conducted by the LAMP method on a nucleic acid sample obtained from a specimen and the amplification product is detected, wherein the FIP in the primer set in th...
|
|
WO/2019/209946A1 |
Disclosed are compositions and methods for determining the nucleotide sequence of sequences of interest using paired-end sequencing. Dumbell circular templates can be generated and used in a rolling circle amplification reaction by ligat...
|
|
WO/2019/208542A1 |
The present invention provides a biomarker for differentiating between Still's disease and septicemia, comprising any of (a) through (d) below: (a) an FGF-2 protein or an FGF-2 transcription product, (b) an IL-18 protein or an IL-18 tran...
|
